ArticleFrontiers in bioengineering and biotechnology2026
Maturation is required to model ischemia-reperfusion injury in engineered human cardiac tissues.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Myocardial infarction remains a leading cause of mortality worldwide, with reperfusion therapy as the clinical standard of care. However, its efficacy is limited by the paradoxical injury caused by ischemia-reperfusion (I/R). Methods: Micro-sized human engineered cardiac tissues (hECTs) were fabricated using induced pluripotent stem cell (iPSC)-derived cardiomyocytes and primary human cardiac fibroblasts in the previously published milliPillar platform and cultured under four conditions integrating metabolic and electrical maturation strategies: standard B27 medium or metabolic maturation medium (MM), each with or without frequency-ramped electrical stimulation. After 28 days of maturation, tissues were subjected to 6 hours of simulated ischemia followed by reperfusion and were assessed for LDH release, cardiac troponin T (cTnT) release, and contractile function over 7 days post-reperfusion. Results: Here, we demonstrate that maturation of a human tissue-engineered cardiac model of I/R injury can recapitulate key features of acute ischemic damage, reperfusion injury, and sustained contractile dysfunction. Modulation of engineered tissue phenotype results in distinct differences in susceptibility to injury and pathological fidelity. Discussion: Notably, electrical stimulation emerges as a critical determinant of I/R injury response, whereas metabolic maturation alone is insufficient to reproduce comparable pathological outcomes. Together, these findings define the structural and functional parameters required to prime cardiac muscle tissues to recapitulate a biologically relevant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.